
Josefin Werme
Articles
-
Jan 15, 2025 |
medrxiv.org | Andrew Grotzinger |Josefin Werme |Wouter J. Peyrot |Oleksandr Frei
J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity) and has received an honorarium for an internal seminar Tempus Labs. K.P.J. is a consultant for Allia Health. A.D.B. has received a speaker fee from Lundbeck.
-
Mar 15, 2024 |
medrxiv.org | Jeanne E. Savage |Josefin Werme |Danielle Dick |Danielle Posthuma
The authors have declared no competing interest. This research was funded by a grant to J.E.S. (VI.VENI.201G-064) from The Netherlands Organization for Scientific Research (NWO) and has been conducted using the UK Biobank Resource (application no. 16406). Analyses were carried out on the Genetic Cluster Computer hosted by the Dutch National computing and Networking Services SURFsara.
-
Sep 7, 2023 |
journals.plos.org | Christiaan de Leeuw |Josefin Werme |Jeanne E. Savage |Wouter J. Peyrot
Loading metrics Open Access Peer-reviewedResearch Article ? This is an uncorrected proof. Citation: de Leeuw C, Werme J, Savage JE, Peyrot WJ, Posthuma D (2023) On the interpretation of transcriptome-wide association studies. PLoS Genet 19(9): e1010921. https://doi.org/10.1371/journal.pgen.1010921Editor: Heather J. Cordell, Newcastle University, UNITED KINGDOMReceived: May 4, 2023; Accepted: August 15, 2023; Published: September 7, 2023Copyright: © 2023 de Leeuw et al.
-
May 3, 2023 |
biorxiv.org | Christiaan de Leeuw |Josefin Werme |Jeanne E. Savage |Wouter J. Peyrot
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →